إعلان
إعلان

TNXP

TNXP logo

Tonix Pharmaceuticals Holding Corp.

16.45
USD
برعاية
+0.83
+5.35%
٠٢ يناير, ١٠:٥٠ UTC -5
مفتوح

تقارير أرباح TNXP

النسبة الإيجابية المفاجئة

TNXP تفوق 21 من 40 آخر التقديرات.

53%

التقرير التالي

بيانات التقرير القادم
١٦ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$2.94M
/
-$3.22
التغير الضمني من Q3 25 (Revenue/ EPS)
-10.61%
/
-10.31%
التغير الضمني من Q4 24 (Revenue/ EPS)
+13.90%
/
-67.04%

Tonix Pharmaceuticals Holding Corp. earnings per share and revenue

On ١٠ نوفمبر ٢٠٢٥, TNXP reported earnings of -3.59 USD per share (EPS) for Q3 25, beating the estimate of -3.65 USD, resulting in a 1.82% surprise. Revenue reached 3.29 مليون, compared to an expected 3.16 مليون, with a 4.05% difference. The market reacted with a +4.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -3.22 USD, with revenue projected to reach 2.94 مليون USD, implying an decrease of -10.31% EPS, and decrease of -10.61% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, Tonix Pharmaceuticals Holding Corp. reported EPS of -$3.59, beating estimates by 1.82%, and revenue of $3.29M, 4.05% above expectations.
The stock price moved up 4.1%, changed from $16.84 before the earnings release to $17.53 the day after.
The next earning report is scheduled for ١٦ مارس ٢٠٢٦.
Based on 5 analysts, Tonix Pharmaceuticals Holding Corp. is expected to report EPS of -$3.22 and revenue of $2.94M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان